HIV Disease Coverage Forecast and Market Analysis to 2024 - ResearchAndMarkets.com

DUBLIN--()--The "HIV Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Market Snapshot

  • B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
  • TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
  • HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
  • Rapid uptake of TAF-based regimens in the US will protect Gilead's revenues following TDF patent expiry.
  • B/F/TAF's potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.

Key Topics Covered:

Forecast: HIV

  • Overview
  • Executive Summary
  • Market Dynamics
  • Forecast And Future Trends
  • Market Definition And Methodology
  • Primary Research Methodology
  • Bibliography
  • Product Profile: Atripla
  • Product Profile (Late Stage): B/F/TAF
  • Product Profile: Complera
  • Product Profile (Late Stage): DOR/3TC/TDF
  • Product Profile: Descovy
  • Product Profile: Genvoya
  • Product Profile: Isentress
  • Product Profile: Juluca
  • Product Profile: Odefsey
  • Product Profile: Prezista Franchise
  • Product Profile: Reyataz Franchise
  • Product Profile: Stribild
  • Product Profile: Symtuza
  • Product Profile: Tivicay
  • Product Profile (Late Stage): Tivicay/Epivir
  • Product Profile: Triumeq
  • Product Profile: Truvada
  • Product Profile (Late Stage): Cabotegravir/Rilpivirine
  • Product Profile (Late Stage): Fostemsavir

Treatment: HIV

  • Overview
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Treatment Guidelines
  • Prescribing Trends
  • Unmet Needs In HIV
  • Impact Of Generics

Epidemiology: HIV

  • Overview
  • Executive Summary
  • Disease Background
  • Sources And Methodology
  • Forecast: HIV
  • Epidemiologist Insight
  • Strengths And Limitations
  • Appendix: Additional Sources
  • Bibliography

Marketed Drugs: HIV

  • Overview
  • Executive Summary
  • Product Overview
  • Product Profile: Atripla
  • Product Profile: Complera
  • Product Profile: Descovy
  • Product Profile: Genvoya
  • Product Profile: Isentress
  • Product Profile: Juluca
  • Product Profile: Odefsey
  • Product Profile: Prezista Franchise
  • Product Profile: Reyataz Franchise
  • Product Profile: Stribild
  • Product Profile: Symtuza
  • Product Profile: Tivicay
  • Product Profile: Triumeq
  • Product Profile: Truvada

Pipeline: HIV

  • Overview
  • Executive Summary
  • Clinical Pipeline Overview
  • Product Profile (Late Stage): B/F/TAF
  • Product Profile (Late Stage): DOR/3TC/TDF
  • Product Profile (Late Stage): Tivicay/Epivir
  • Product Profile (Late Stage): Cabotegravir/Rilpivirine
  • Product Profile (Late Stage): Fostemsavir

For more information about this report visit https://www.researchandmarkets.com/research/hqhkfh/hiv_disease?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: HIV/AIDS Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: HIV/AIDS Drugs